Comparative analysis of serological reactivity in genetically confirmed Rh variants within a recipient population.

IF 1.6 4区 医学 Q3 HEMATOLOGY
Vox Sanguinis Pub Date : 2026-05-08 DOI:10.1111/vox.70285
Maïlis Lauwers, Philippe Akiki, Samy Bensaid, Saad Bakrim, Mélanie Monfort, Hanane El Kenz
{"title":"Comparative analysis of serological reactivity in genetically confirmed Rh variants within a recipient population.","authors":"Maïlis Lauwers, Philippe Akiki, Samy Bensaid, Saad Bakrim, Mélanie Monfort, Hanane El Kenz","doi":"10.1111/vox.70285","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Detecting Rh variants in transfusion recipients is essential to prevent alloimmunization. This study compared the serological reactivity of various monoclonal antibodies using two techniques (gel column agglutination and microplate technology at room temperature) in relation to genetically confirmed Rh variants.</p><p><strong>Materials and methods: </strong>Over an 18-month period, all EDTA blood samples referred to the molecular laboratory were analysed. RHD and RHCE genotyping was performed, and samples carrying at least one variant allele underwent serological testing. Statistical analysis was performed using the McNemar test (p < 0.05).</p><p><strong>Results: </strong>Among 610 samples, 118 (19%) carried at least one Rh variant. The most frequent alleles were RHCE*CeRN (n = 39) and RHD*weak D type 1 (n = 14). Weak RhD (types 1 and 3) and partial RhD from RHD*DAR were serologically weakened (<4+) with both methods. Homozygosity for RHCE*CeRN was suggested by serological weakening of RH5 with both methods, whereas heterozygosity was indicated by serological weakening of RH2 with microplate only. Other variants with a few samples (RH1 of RHD*weak D type 2 and 5, RH2 of RHD*RHD-CE (4-7)-D, RH3 of RHCE*cEIV, RH4 of RHCE*ceJAL and RH5 of RHCE*ceMO.01 and RHCE*ceAR) showed weak serological intensities but lacked statistical confirmation. Finally, 39% of Rh variants were not detected as serologically weakened by both serological methods.</p><p><strong>Conclusion: </strong>Phenotyping remains the first-line screening tool. Weak serological intensities help guide molecular investigations. However, detection of Rh variants using serology alone is highly variable. Combining different clones and techniques improves sensitivity.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70285","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Detecting Rh variants in transfusion recipients is essential to prevent alloimmunization. This study compared the serological reactivity of various monoclonal antibodies using two techniques (gel column agglutination and microplate technology at room temperature) in relation to genetically confirmed Rh variants.

Materials and methods: Over an 18-month period, all EDTA blood samples referred to the molecular laboratory were analysed. RHD and RHCE genotyping was performed, and samples carrying at least one variant allele underwent serological testing. Statistical analysis was performed using the McNemar test (p < 0.05).

Results: Among 610 samples, 118 (19%) carried at least one Rh variant. The most frequent alleles were RHCE*CeRN (n = 39) and RHD*weak D type 1 (n = 14). Weak RhD (types 1 and 3) and partial RhD from RHD*DAR were serologically weakened (<4+) with both methods. Homozygosity for RHCE*CeRN was suggested by serological weakening of RH5 with both methods, whereas heterozygosity was indicated by serological weakening of RH2 with microplate only. Other variants with a few samples (RH1 of RHD*weak D type 2 and 5, RH2 of RHD*RHD-CE (4-7)-D, RH3 of RHCE*cEIV, RH4 of RHCE*ceJAL and RH5 of RHCE*ceMO.01 and RHCE*ceAR) showed weak serological intensities but lacked statistical confirmation. Finally, 39% of Rh variants were not detected as serologically weakened by both serological methods.

Conclusion: Phenotyping remains the first-line screening tool. Weak serological intensities help guide molecular investigations. However, detection of Rh variants using serology alone is highly variable. Combining different clones and techniques improves sensitivity.

受体人群中经遗传证实的Rh变异血清学反应性的比较分析。
背景和目的:检测输血受者的Rh变异对预防同种异体免疫至关重要。本研究使用两种技术(凝胶柱凝集和室温微孔板技术)比较了各种单克隆抗体与基因确认的Rh变异的血清学反应性。材料和方法:在18个月的时间里,所有EDTA血液样本送交分子实验室进行分析。进行RHD和RHCE基因分型,并对携带至少一个变异等位基因的样本进行血清学检测。使用McNemar检验进行统计分析(p)结果:在610份样本中,118份(19%)携带至少一种Rh变异。最常见的等位基因为RHCE*CeRN (n = 39)和RHD*弱D型1 (n = 14)。来自RhD *DAR的弱RhD(1型和3型)和部分RhD在血清学上减弱(结论:表型仍然是一线筛查工具)。弱血清学强度有助于指导分子调查。然而,仅使用血清学检测Rh变异是高度可变的。结合不同的克隆和技术可以提高灵敏度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vox Sanguinis
Vox Sanguinis 医学-血液学
CiteScore
4.40
自引率
11.10%
发文量
156
审稿时长
6-12 weeks
期刊介绍: Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书